Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy

Haas, Sanne de; Delmar, Paul; Bansal, Aruna T.; Moisse, Matthieu; Miles, David; Leighl, Natasha B.; Escudier, Bernard; Cutsem, Éric Van; Carmeliet, Peter; Scherer, Stefan; Pallaud, Céline; Lambrechts, Diether

doi:10.1007/s10456-014-9438-1

Cited by 43 publications

(41 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Only a meta-analysis from six randomized phase III trials evaluating bevacizumab-treated patients diagnosed of six different types of tumors includes 59 cases of renal cancer, and a non-significant association was found [20].…”

Section: Bevacizumab and Sorafenibmentioning

confidence: 98%

Predictive biomarker candidates to delineate efficacy of antiangiogenic treatment in renal cell carcinoma

et al. 2015

View full text Add to dashboard Cite

Antiangiogenic therapy is currently considered as the cornerstone of treatment in metastatic kidney cancer. A monoclonal antibody against the vascular endothelial growth factor (VEGF) and several tyrosine kinase inhibitors targeting the VEGF receptors demonstrated, 7 years ago, to deeply impact the outcome of this tumor and became a model of integration of molecular knowledge into clinical practice. Unfortunately, no further improvement in survival has been made and 20-25 % of cases remain primary refractory to these drugs, with an overall dismal prognosis. Since biomarker predictors of activity are lacking, their development could highly help in the process of making clinical decisions when choosing the best option for every patient or prompting the inclusion in clinical trials. This unmet medical need could become even more relevant if new immunotherapy confirms its initial promising results in this pathology. In this article, we provide an insight of current state of the art regarding the prediction of antiangiogenic efficacy in kidney cancer and propose new strategies for the implementation of such markers in clinical practice.

show abstract

Section: Bevacizumab and Sorafenibmentioning

confidence: 98%

Predictive biomarker candidates to delineate efficacy of antiangiogenic treatment in renal cell carcinoma

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Although mechanistic explanations of the contribution of polymorphisms to disease progression and/or treatment response are not always available, they are a useful tool to select patients that will maximally benefit from therapy (de Haas et al, 2014) or predict adverse side effects (Lambrechts et al, 2014). Van der Veldt et al (2011) studied polymorphisms of genes involved in sunitinib pharmacokinetics, and variations in the drug-converting enzyme CYP3A5 and efflux transporter ABCB1 were associated with enhanced progression-free survival in sunitinib-treated patients with metastatic renal cell cancer.…”

Section: F Emerging Mechanisms Of Resistancementioning

confidence: 99%

The Great Escape; the Hallmarks of Resistance to Antiangiogenic Therapy

et al. 2015

View full text Add to dashboard Cite

“…41 A recent study showed that variable expression of VEGF-A, VHL, and VEGF-C along with other genes may predict the efficacy of bevacizumab. 15 Other molecular markers or factors are probably also important in regulating the therapeutic efficacy of bevacizumab. Both anti-VEGF and anti-HIF1a treatments have shown limited efficacy in managing intracranial tumors and have not yet been fully investigated for hemangioblastomas.…”

Section: Hemangioblastomasmentioning

confidence: 99%

The genetic basis of intradural spinal tumors and its impact on clinical treatment

Karsy

Guan

Sivakumar

et al. 2015

FOC

View full text Add to dashboard Cite

Genetic alterations in the cells of intradural spinal tumors can have a significant impact on the treatment options, counseling, and prognosis for patients. Although surgery is the primary therapy for most intradural tumors, radiochemothera-peutic modalities and targeted interventions play an ever-evolving role in treating aggressive cancers and in addressing cancer recurrence in long-term survivors. Recent studies have helped delineate specific genetic and molecular differences between intradural spinal tumors and their intracranial counterparts and have also identified significant variation in therapeutic effects on these tumors. This review discusses the genetic and molecular alterations in the most common intradural spinal tumors in both adult and pediatrie patients, including nerve sheath tumors (that is, neurofibroma and schwannoma), meningioma, ependymoma, astrocytoma (that is, low-grade glioma, anaplastic astrocytoma, and glioblastoma), hemangioblastoma, and medulloblastoma. It also examines the genetics of metastatic tumors to the spinal cord, arising either from the CNS or from systemic sources. Importantly, the impact of this knowledge on therapeutic options and its application to clinical practice are discussed.

show abstract

Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy

Cited by 43 publications

References 53 publications

Predictive biomarker candidates to delineate efficacy of antiangiogenic treatment in renal cell carcinoma

Predictive biomarker candidates to delineate efficacy of antiangiogenic treatment in renal cell carcinoma

The Great Escape; the Hallmarks of Resistance to Antiangiogenic Therapy

The genetic basis of intradural spinal tumors and its impact on clinical treatment

Contact Info

Product

Resources

About